Anavex Life Sciences
Veridion Score
Composite trend over time
Why is AVXL moving today?
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for AVXL.
AVXL insider activity
Anavex Life Sciences
No multi-insider buying cluster in the last 90 days
Mixed: Not disclosed across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
The current Form 4 feed did not return value-bearing open-market rows for AVXL.
AVXL contract awards, year to date.
Public federal awards linked to this ticker.
AVXL lobbying filings, year to date.
Registered lobbying filings matched to Anavex Life Sciences.